Among type 1 diabetes patients receiving insulin treatment, a higher percentage of patients in the sotagliflozin group achieved glycated hemoglobin levels below 7.0%, with no occurrence of severe hypoglycemia or diabetic ketoacidosis, compared to the placebo group. The gene discussed is INS; the disease is Hypoglycemia.